Inferra AI / Company / HRMY

Harmony Biosciences Holdings, Inc.

HRMY · Health Care

Last earnings Aug 4, 2026

Key results

Profile WAKIX Net revenuequarter

30%

Best-in-Class Profile WAKIX Net Revenue Grew 30% Year over Year to $261.3 Million for Second Quarter 2026

SEC original ↗Harmony Biosciences Holdings, Inc. — Earnings release (8-K exhibit)EX-99Aug 4, 2026

Revenuequarter

$261.3 million

(Nasdaq: HRMY) today reported Q2 2026 net revenue for WAKIX (pitolisant) of $261.3 million, delivering 30% year-over-year growth in its seventh year on the market.

SEC original ↗Harmony Biosciences Holdings, Inc. — Earnings release (8-K exhibit)EX-99Aug 4, 2026

Our record second-quarter revenue reflects sustained demand for WAKIX and keeps us firmly on track to deliver over $1 billion in revenue this year.

SEC original ↗Harmony Biosciences Holdings, Inc. — Earnings release (8-K exhibit)EX-99Aug 4, 2026

revenue of $261.3 million for the quarter ended June 30, 2026, compared to $200.5 million for the same period in 2025, representing 30% year-over-year growth.

SEC original ↗Harmony Biosciences Holdings, Inc. — Earnings release (8-K exhibit)EX-99Aug 4, 2026

Cost of product sold was $63.2 million in the second quarter of 2026, or 24.2% as a percentage of net product revenue, as compared to $38.2 million, or 19.0%, for the same quarter in 2025, representing a 66% increase.

SEC original ↗Harmony Biosciences Holdings, Inc. — Earnings release (8-K exhibit)EX-99Aug 4, 2026

Net incomequarter

$75.4 million

Net income for the second quarter was $75.4 million, or $1.28 per diluted share, compared to $39.8 million, or $0.68 per diluted share, for the same quarter in 2025.

SEC original ↗Harmony Biosciences Holdings, Inc. — Earnings release (8-K exhibit)EX-99Aug 4, 2026

B Net revenuequarter

$1B

prior year; 40% CAGR over past 5 years • +450 Net Patient Adds, 8,950 Average Patients BEST-IN-CLASS OX2R POTENTIAL BP-205 • Encouraging single ascending dose (SAD) data; potential for once-daily dosing and favorable safety/tolerability profile • Most potent of OX2R agonists currently in the clinic • Investing in robust Phase 2 development program toward multiple CNS Indications Value Inflection: On Track For >$1B Net Revenue in 2026 & Multiple BP-205 Data Catalysts Ahead GROWING ADVANCING 3 Harmony Biosciences | Q2 2026 Financial Results & Business Update | All rights reserved.

SEC original ↗Harmony Biosciences Holdings, Inc. — Presentation / slide deck (8-K exhibit)EX-99Aug 4, 2026

AI analysis

Q2 2026 · reported Aug 4, 2026

Based on: Earnings release + Q2 2026 deck + parent 8-K + 10-Q — transcript not held

Revenue · Q2 2026

$261.3M

EX-99 · Aug 4, 2026

Diluted EPS · Q2 2026

$1.28

EX-99 · Aug 4, 2026

Net income · Q2 2026

$75.4M

EX-99 · Aug 4, 2026

B Net revenue · Q2 2026

$1B

EX-99 · Aug 4, 2026

The quarter in charts

Guidance ladder — revenue

Delivered vs the company's guided range

Q2 2026 delivered$261.3M

Guided range (company-stated)$1.0B · midpoint $1.0B

0$B

EX-99 · Aug 4, 2026 Guide as stated by the company; range and midpoint computed from the stated figure.

Headline figures

Metric	Q2 2026	Prior qtr	Year ago
Profile WAKIX Net revenue	30%	—	—
Revenue	$261.3 million	$215.4 million	—
Net income	$75.4 million	$32.5 million	—
B Net revenue	$1B	—	—

EX-99 · Aug 4, 2026

Guidance · company-stated

Net Revenue$1.0 Billion

Midpoint vs latest-quarter revenue+282.7%computed from stated figures

Guidance stated in the release for Second Quarter 2026; figures as stated.

Next earningsNo verified date on fileNo date is estimated or imported

Capital allocation

Investments in available-for-sale debt securities are classified as Level 2 and carried at fair value, which we estimate utilizing a third-party pricing service.

Cash, Cash Equivalents and Restricted Cash Cash and cash equivalents and restricted cash consist of cash and, if applicable, highly liquid investments with an original maturity of three months or less when purchased, including investments in money market funds and debt securities that approximate fair value.

What changed vs last quarter

Guide midpoint vs latest-quarter revenue +282.7% computed from stated figures

General educational research only — not investment advice.Every figure is as stated in the held documents; values marked “computed from stated figures” are arithmetic on those stated figures. Guidance shown is the company’s own stated guidance. No price targets, no recommendations, no consensus estimates.

Event summary

These results underscore continued strong demand for WAKIX, disciplined commercial execution across the franchise and sustained momentum through the first half of 2026

Based on: Earnings release + Q2 2026 deck + parent 8-K + 10-Q — transcript not held

Guidance & outlook

Net Revenue: “Net Revenue Guidance of $1.0 Billion to $1.04 Billion”

Net Revenue (“Second Quarter 2026”)
“nline portal and changes to reimbursement support process to enable patients to secure WAKIX faster and with higher success rate On Track to Achieve 2026 WAKIX Net Revenue Guidance of $1.0 Billion to $1.04 Billion Advance a Robust, Self-Funded Pipeline Orexin-2 receptor agonist BP-205 (BP1.15205) is Harmony s OX2R agonist discovered by Teijin Pharma and developed in part”

Guidance stated in the release for Second Quarter 2026; figures as stated.

Capital allocation

Investments in available-for-sale debt securities are classified as Level 2 and carried at fair value, which we estimate utilizing a third-party pricing service.

SEC original ↗Harmony Biosciences Holdings, Inc. — 10-Q Quarterly report10-QAug 4, 2026

Investments The Company s investments consist of debt securities that are classified as available-for-sale.

SEC original ↗Harmony Biosciences Holdings, Inc. — 10-Q Quarterly report10-QAug 4, 2026

Interest income earned on cash and investment balances, accretion of the discount on investments in debt securities, amortization of premiums and realized gains and losses, if any, are recorded in interest income in the unaudited condensed consolidated statement of operations and comprehensive income.

SEC original ↗Harmony Biosciences Holdings, Inc. — 10-Q Quarterly report10-QAug 4, 2026

Share Repurchases The Company accounts for share repurchases as constructive retirements, whereby it reduces common stock and additional paid-in capital by the amount of the original issuance, with any excess purchase price recorded as a reduction to retained earnings.

SEC original ↗Harmony Biosciences Holdings, Inc. — 10-Q Quarterly report10-QAug 4, 2026

Under this method, issued and outstanding shares of common stock are reduced by the amount of shares of common stock repurchased, and no treasury stock is recognized on the condensed consolidated financial statements.

SEC original ↗Harmony Biosciences Holdings, Inc. — 10-Q Quarterly report10-QAug 4, 2026

Strategy & priorities

These data support Harmony s robust orexin development strategy, including initiating Phase 2 studies beginning in mid-2027 to evaluate multiple CNS indications.

SEC original ↗Harmony Biosciences Holdings, Inc. — Earnings release (8-K exhibit)EX-99Aug 4, 2026

All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including statements regarding our full year 2026 net product revenue, expectations for the growth and value of WAKIX, our planned and ongoing clinical trials and expected timing of data readouts, anticipated regulatory milestones, our future results of operations and financial position, business strategy, products, prospective products, product approvals, and the plans and objectives of management for future operations.

SEC original ↗Harmony Biosciences Holdings, Inc. — Earnings release (8-K exhibit)EX-99Aug 4, 2026

All statements contained in this presentation that do not relate to matters of historical fact should be considered forward-looking statements, including statements regarding our full year 2026 net product revenue, expectations for the growth and value of WAKIX, our planned and ongoing clinical trials and expected timing of data readouts, anticipated regulatory milestones, our future results of operations and financial position, business strategy, products, prospective products, product approvals, and the plans and objectives of management for future operations.

SEC original ↗Harmony Biosciences Holdings, Inc. — Presentation / slide deck (8-K exhibit)EX-99Aug 4, 2026

To date, we have focused on rare neurological diseases with a growing portfolio now spanning sleep/wake and rare epilepsy, and we are harnessing scientific insights and pioneering approaches to advance meaningful treatments that help patients thrive.

SEC original ↗Harmony Biosciences Holdings, Inc. — 10-Q Quarterly report10-QAug 4, 2026

Risks & headwinds

Legal Proceedings 44 Item 1A.

SEC original ↗Harmony Biosciences Holdings, Inc. — 10-Q Quarterly report10-QAug 4, 2026

Significant Risks and Uncertainties The Company s operations are subject to a number of factors that can affect its operating results and financial condition.

SEC original ↗Harmony Biosciences Holdings, Inc. — 10-Q Quarterly report10-QAug 4, 2026

COMMITMENTS AND CONTINGENCIES Legal Proceedings From time to time, the Company is subject to claims and suits arising in the ordinary course of business.

SEC original ↗Harmony Biosciences Holdings, Inc. — 10-Q Quarterly report10-QAug 4, 2026

As of June 30, 2026, there were no material claims or lawsuits outstanding other than the Abbreviated New Drug Application ( ANDA ) litigation discussed below .

SEC original ↗Harmony Biosciences Holdings, Inc. — 10-Q Quarterly report10-QAug 4, 2026

ANDA Litigation In September 2023, the Company and its licensor, Bioprojet, received notice from Lupin Limited ( Lupin ) pursuant to 21 U.

SEC original ↗Harmony Biosciences Holdings, Inc. — 10-Q Quarterly report10-QAug 4, 2026

Under the terms of the settlement agreement, the litigation between the parties in the United States District Court for the District of Delaware will be dismissed, and Lupin will have a license to sell its generic product beginning July 2030 if WAKIX receives pediatric exclusivity, or earlier under certain circumstances.

SEC original ↗Harmony Biosciences Holdings, Inc. — 10-Q Quarterly report10-QAug 4, 2026

What changed vs prior quarter

Revenue — prior quarter passage and this quarter's passage are both cited.

SEC original ↗Harmony Biosciences Holdings, Inc. — Earnings release (8-K exhibit)EX-99Aug 4, 2026

Net income — prior quarter passage and this quarter's passage are both cited.

SEC original ↗Harmony Biosciences Holdings, Inc. — Earnings release (8-K exhibit)EX-99Aug 4, 2026

Documents

Earnings deck slides

0 decks with slide view

Harmony Biosciences Holdings, Inc. — Presentation / slide deck (8-K exhibit) — Slide view unavailable — this deck was filed as a web document, whose text has no page boundaries.

Competitors